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Summarizing discussion
Functional polymorphisms in receptors for IgG (FcyR), affecting IgG binding, were
first described in 1983, when a clear non-responder population was identified in the
mitogenic effect on T cells of mouse IgGl anti-CD3 antibodies (1). In the following
years, our knowledge of structural diversity and heterogeneity in FcyR increased
substantially, and clinical consequences of this variety became apparent (2,3). With the
development of single and multiple Fc receptor deficient mice in the past decade, our
view on Fc receptor interactions in the inflammatory response changed markedly (4,
Chapter 1). More recent findings force us to revise our view on the involvement of
FcyR polymorphisms in this response as well (Chapter 9).
New insights in FclR heterogeneity and function contribute considerably to our
understanding of the pathophysiology of various autoimmune and infectious diseases
(2-4). In particular for immune complex-mediated iseases, such as systemic lupus
erythematosus (SLE), recent advances in our knowledge have important consequences
(Chapter 1). This thesis addresses the effect of genetic diversity and differential FcyR-
mediated responses on systemic autoimmune disease, in particular wrth regard to
clearance of immune complexes and the development of inflammation.
Heterogeneity of FcyR in autoimntune disease
Genetically-determined variation with functional consequences has been described for
FcyRIIa, FcIRIIIa and FcyRIIIb, including the arginine (R) to histidine (H) change at
amino acid position 131 for FcyRIIa, the valine (V) to phenylalanine (F) change at
amino acid position 158 for FcyRIIIa, and the four amino acid changes termed
neutrophil antigen polymorphism (NA1 and NA2) for FcyRIIIb (5-7). The effect of this
variation is most pronounced for FcyRIIa, as the FcyRIIa-Hl31 allele was shown to be
crucial for firm binding of lgG2-containing complexes (5,8), phagocytosis of IgG2-
opsonized bacteria (7,9,10), and the mitogenic effect on T cells of human IgG2 anti-
CD3 antibodies (11), which requires firm binding to FcyRIIa-H131 for adequate cross-
linking of CD3. Although several association studies have demonstrated marked
skewing towards low-binding alleles (FcyRIIa-Rl31, FcyRIIIa-FI58 and FcyRIIIb-
NA2) in patients with autoimmune diseases such as SLE, discrepancies between
different studies exist (2,3). Inconsistencies may arise from variation in population
sizes, clinical criteria used to define disease, as well as ethnic differences between
populations (12).
In Chapter 2, we determined the influence of all 3 functional FcyR polymorphisms
on susceptibility to SLE in a large and strictly Caucasian population, using well-
defined and universally acknowledged criteria for disease. In this study, we found a
strong trend toward skewing of FcyRIIa, with an enrichment of the homozygous low-
binding genotype in patients compared with controls. This association was confirmed
in a partly overlapping study population, but shown to be independent of single
nucleotide polymorphisms in the interleukin-lO gene promotor (Chapter 4). Both
FcyRIIa and IL-10 are located on chromosome 1, and have been indicated as potential
susceptibility loci for SLE in genome scans (13,14). In contrast to previous
observations (2,3), we did not find a correlation between low-binding alleles of
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FcyRIIa, nor of FcyRIIIa, and the development of lupus nephritis. Due to discrepancies
between different studies, a thorough meta-analysis is warranted to determine the exact
contribution of different FcyR polymorphisms to disease susceptibility and clinical
manifestations in SLE.
We also determined the influence of all 3 FcyR polymorphisms on susceptibility to
Wegener's granulomatosis (WG), a systemic vasculitis with chronic nasal carriage of
Staphylococcus aureus (S aureus) as an important risk factor for disease relapses
(Chapter 3). Interestingly, patients with WG were more prone to relapse in the first
hve years after diagnosis when homozygous for the low-binding alleles of both
FcyRIIa and FcyRIIIa. As these polymorphic variants are associated with decreased Fc
receptor mediated clearance (7,9,10), this finding may be relevant for the chronic nasal
carriage of S aureus in patients, and the subsequent risk to develop a disease relapse
(15). Furtherrnore, this study was the first to demonstrate combinations of particular
FcyR alleles to contribute to disease susceptibility. Although such allelic combinations
could be of relevance in SLE as well, we were unable to demonstrate this (Chapter 2).
Studies in mice have recently shown an important role for FcyRIIb in the regulation
of autoimmunity (16-18). This receptor is unique in its ability to transmit inhibitory
signals, and is generally believed to act as an inflammation inhibiting receptor
(Chapter 1). In Chapter 5, we screened the FcyRIIB gene for allelic variation, and
determined whether specific alleles were associated with SLE in a Japanese population.
For the first time, a single nucleotide polymorphism in FcyRIIB was detected in
humans, resulting in an isoleucine to threonine change at amino acid position 232
within the transmembrane region of the molecule. Moreover, we found that the
homozygous FcyRIIb-T/T232 genotype was significantly enriched in patients with
SLE, compared with controls. Although functional differences between these two
alleles remain to be determined, a recent study on deletion mutants of FcyRIIb revealed
the transmembrane region of this molecule to contribute to its function (19). A
confirmation of this polymorphism in Caucasian populations, as well as its contribution
to disease susceptibility, is now eagerly awaited.
Clearance of inmune complexes
As FcyR polymorphisms mediate binding and phagocytosis of immune complexes (5-
10), they may also influence clearance of circulating immune complexes in vivo.
Clearance of immune complexes is normally regulated efficiently by the mononuclear
phagocyte system (MPS). In this system, erythrocytes bind immune complexes via
complement receptor 1, providing a transport mechanism to mononuclear phagocytes
located in liver and spleen. The complexes are subsequently removed from the
erythrocytes, and intemalized by fixed tissue phagocytes. The importance of FcyR in
this process has been demonstrated clearly by studies of FcyR blockade in primates
(20) and mice (21). In Chapter 2, we were able to show that the R-H polymorphism of
FcyRIIa affects clearance of immune complexes in humans as well, as demonstrated by
an extended half-life in blood of IgG-coated erythrocytes in subjects homozygous for
the low-binding allele of FcyRIIa. This finding could explain the observed skewing
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towards this genotype in patients with SLE (Chapter 2 and 4), as reduced clearance of
imrnune complexes may -indeed- influence the development of this disease.
To examine the role of FcyR in MPS function in more detail, we studied the
processing of labeled immune complexes in mice deficient for different FcyR (FcyRI,
FcyRII or FcyRIII). As described in Chapter 6, the liver was lbund to be the primary
organ of imrnune complex uptake in mice. Clearance of immune complexes to the liver
was substantially reduced when FcyRII was not present, whereas the absence of FcyRI
or FcyRIII did not influence liver uptake. FcyRII in mice is analogous to FcyRIIb in
lrurnans, and is an inflammation inhibiting receptor. Indeed, in vivo production of the
pro-inflammatory cytokine IL-6 in response to immune complex clearance was
significantly reduced in the absence of FcyRI and FcyRIII. Tliese findings allude to an
irnportant role for FcyRII in MPS function, as this receptor is efficient in immune
complex clearance without improper production of pro-inflammatory cytokines. In
view of this, we propose FcyRII to be the primary receptor for non-inflammatory IC
clearance by the MPS in mice. It now remains a matter of debate rvhether MPS
regulation in humans is predominantly at the level of activating receptors such as
FcyRIIa, or the irrhibitory receptor FcyRIIb.
Inflamnntion in autoinmune clisease
When handling of imntune complexes by the MPS is impaired, subsequent tissue
deposition of complexes may result in inflammation and tissue damage. IgG subclasses
differ in their potential to induce an inflanrmatory response, as they differentially
interact with FcyR and complement. In Chapter 7, we investigated the influence of
different autoantibody subclasses on the development of renal and extra-renal relapses
in patients with SLE. Autoantibodies closely associated with renal involvement in SLE
are cofirmonly directed against dsDNA and nucleosomes (22). Indeed, in the majonty
of patients, a renal relapse is preceded by a significant rise in anti-dsDNA IgG (23).In
our study, we found that IgG2 and IgG3 antibodies to nucleohistone were present more
often in plasma of patients with a renal relapse compared to patients with an extra-renal
relapse. Moreover, a significant rise in IgG2 anti-nucleohistone preceded a renal
relapse in 78o/o of patients, compared to lSYo of patients with an extra-renal relapse.
For antibodies to dsDNA, only a significant rise in IgGl could be detected prior to a
renal relapse, although lgG2 antibodies were overrepresented in these patients. These
data implicate a role for FcyR polymorphisms in the development of lupus nephritis,
although we could not demonstrate such an involvement in our association study
(Chapter 2).
The results of this study prompted us to investigate renal FcyR expression in more
detail. Although FcyR have never been detected in frozen tissue sections of renal
biopsy specimens frorn healthy donors (24,25), in vitro studies have shown expression
of FcyRI and FcyRIIIa to be induced on cultured human mesangial cells upon
stimulation with LPS and/or IFNy (26,27). In Chapter 8, we therefore exarnined
whether FcyR expression could be detected in frozen tissue sections of renal biopsy




of any class of FcyR, although infiltrating leukocytes, presumably monocytes, were
found positive in the majority of patients. These findings are in accordance with
reconstitution studies in FcyR deficient mice, confirming FcyR-mediated activation by
immune complexes deposited in kidney to be triggered by bone-marrow derived,
circulating effector cells, rather than resident (mesangial) cells (4).
A challenging new concept in our understanding of inflammation is the influence of
differential FcyR-mediated responses, which has been elegantly shown in panels of Fc
receptor deficient animal models (4, Chapter 1). In this respect, FcyR polymorphisms
may also modulate the severity of an inflammatory response. In Chapter 9, we
investigated effector functions of neutrophils and monocytes upon activation with
human IgG subclasses in donors expressing low-binding or high-binding FcyR alleles,
in particular with regard to FcyRIIa. In contrast o our expectations, we did not find
differences in cellular activation by IgGl or IgG2 between different donors, despite an
apparent distinction in firm IgG2 binding. This finding is in favour of a new
mechanism for IgG-mediated leukocyte activation, in which a low-affinity interaction
between IgG and FcyR appears to be sufficient to generate an inflammatory response,
independent ofIgG subclass and FcyR genotype ofthe host.
The implications of these findings for the inflammatory response in a disease such
as SLE are profound. When clearance of immune complexes is impaired in the
presence of low-binding FcyR alleles, our results suggest that the host is still capable of
mounting adequate ffector cell responses. Persistence of immune complexes, as is the
case in SLE, may thus lead to excessive inflammatory responses, that can eventually be
detrimental to the host. Conversely, in inflammatory processes that do not involve
clearance of immune complexes, a correlation between IgG-mediated activation and
FcyR polymorphisms will probably not be observed. This may also explain why we
detect skewed distribution of FcyR alleles in susceptibility to SLE, but not in renal
involvement, as an inflammatory response will be triggered independent of the FcyR
genotype of the host once immune complexes are deposited (Chapter 2).
Concluding remarks
Whereas this thesis primarily focused on the effect of genetic diversity and differential
FcyR-mediated responses on systemic autoimmune disease, it should be noted that
other factors also contribute to clearance of immune complexes and development of
inflammation. An important role for the complement system in processing of immune
complexes has been supported by human studies showing abnormal immune complex
clearance in complement-deficient and hypocomplementaemic patients, including
patients with SLE (28,29). A critical role for complement has been demonstrated in the
clearance of apoptotic cells as well (30), an important aspect of SLE pathophysiology.
Indeed, it is intriguing that in more than 90 percent of patients with a Clq deficiency,
this defect alone is sufficient to develop an SLE-like syndrome. However, it remains a
matter of debate whether complement activation is crucial to the development of
inflammation and tissue damage (31-33). An important role for activating FcyR has
been suggested in this respect, using various animal models for human diseases (4,
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Chapter 1). Furthermore, pathologic antibodies in SLE are often of the IgG2 subclass,
a subclass that does not activate compliment efficiently, which is in support of a
dominant role for FcyR in inflammation (34,35, Chapter 7). In view of these findings,
it is likely to assume that complex diseases such as SLE develop and aggrevate in the
presence of multiple abnormalities. Future research should clarifo the exact role of
each factor in the development and progression of autoimmune disease, including the
contribution of individual FcvR.
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